Canada
· Delayed Price · Currency is CAD Rakovina Therapeutics Company Description
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.
Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors.
It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer.
Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.
Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mads Daugaard |
Contact Details
Address: 999 West Broadway Vancouver, British Columbia V5Z 1K5 Canada | |
| Website | rakovinatherapeutics.com |
Stock Details
| Ticker Symbol | RKV |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA75103L1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mads Daugaard Ph.D. | President, Chief Executive Officer and Chief Scientific Officer |
| Jeffrey A. Bacha B.Sc., M.B.A. | Executive Chairman |
| David Hyman CA, CBV | Chief Financial Officer and Corporate Secretary |
| Dr. John Langlands Ph.D. | Chief Operating Officer |
| Michelle Seltenrich M.B.A., MBA | Director of Corporate Development |